(Q48299990)

10 February 2018

title

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. (English)

1 reference

10 February 2018

1 reference

1 reference

14

Henry S Friedman

1 reference

10 February 2018

11

Sridharan Gururangan

1 reference

10 February 2018

1

Annick Desjardins

1 reference

10 February 2018

5

Allan H Friedman

1 reference

10 February 2018

15

David A Reardon

1 reference

10 February 2018

7

Roger E McLendon

1 reference

10 February 2018

Jeremy N Rich

9

Jeremy N Rich

1 reference

10 February 2018

Jennifer J Quinn

2

Jennifer A Quinn

1 reference

10 February 2018

James J Vredenburgh

3

James J Vredenburgh

1 reference

10 February 2018

James M Provenzale

8

James M Provenzale

1 reference

10 February 2018

Sith Sathornsumetee

4

Sith Sathornsumetee

1 reference

10 February 2018

James H. Herndon

6

James E Herndon

1 reference

10 February 2018

Jeannette M Dowell

12

Jeannette M Dowell

1 reference

10 February 2018

August Salvado

13

August Salvado

1 reference

10 February 2018

author name string

John H Sampson

10

1 reference

10 February 2018

publication date

24 January 2007

1 reference

10 February 2018

Journal of Neuro-Oncology

published in

1 reference

10 February 2018

volume

83

1 reference

10 February 2018

page(s)

53-60

1 reference

10 February 2018

issue

1

1 reference

10 February 2018

https://scigraph.springernature.com/pub.10.1007/s11060-006-9302-2

exact match

0 references

cites work

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

1 reference

12 December 2020

Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors

1 reference

12 December 2020

A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma

1 reference

12 December 2020

1 reference

12 December 2020

Primary brain tumours in adults.

1 reference

12 December 2020

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

12 December 2020

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

1 reference

12 December 2020

Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis

1 reference

12 December 2020

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.

1 reference

12 December 2020

Anaplastic astrocytoma: diagnosis, prognosis, and management

1 reference

12 December 2020

Adjuvant chemotherapy in the treatment of high grade gliomas.

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

A Phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas

1 reference

12 December 2020

The place of hydroxyurea in the treatment of primary brain tumors

1 reference

12 December 2020

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

12 December 2020

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

12 December 2020

Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group.

1 reference

12 December 2020

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

1 reference

12 December 2020

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

1 reference

12 December 2020

10.1007/S11060-006-9302-2

Identifiers

DOI

1 reference

10 February 2018

PubMed ID

17245623

1 reference

10 February 2018